The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B
The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B
复制标题
DOI：
10.1002/ijc.29532
复制
发表时间：
2015-10-01
影响因子：
6.4
通讯作者：
Unkila-Kallio, Leila
中科院分区：
文献类型：
--
作者：
Farkkila, Anniina;Koskela, Sanna;Unkila-Kallio, Leila
卵巢成人型颗粒细胞瘤（AGCT）需要长期随访，但缺乏关于最佳随访标志物的证据。本研究的目的是验证血清抗苗勒管激素（AMH）和目前的标志物β-淀粉样蛋白B作为AGCT的单一和联合标志物的临床实用性。我们对123例绝经前和绝经后AGCT患者进行了纵向、部分前瞻性队列研究，中位随访时间为10.5年（范围0.3-50.0年）。采用免疫酶法检测560例患者治疗前和随访时血清AMH和AMB B水平。我们发现在原发性或复发性AGCT患者中，血清AMH和AMB B水平显著升高。两种标志物的水平与肿瘤大小呈正相关（p
Ovarian adult-type granulosa cell tumors (AGCTs) require prolonged follow-up, but evidence regarding the optimal follow-up marker is lacking. The objective of our study was to validate the clinical usefulness of serum anti-Mullerian hormone (AMH) and the current marker inhibin B as single and combined markers of AGCTs. We conducted a longitudinal, partially prospective cohort study of 123 premenopausal and postmenopausal AGCT patients with a median follow-up time of 10.5 years (range 0.3-50.0 years). Serum AMH and inhibin B levels were measured from 560 pretreatment and follow-up serum samples by using immunoenzymometric assays. We found that serum AMH and inhibin B levels were significantly elevated in patients with primary or recurrent AGCTs. The levels of both markers positively correlated to tumor size (p